• News Releases

New medication options in behavioral health

Jun 24th, 2022

FDA Approves 14 New Medications

The FDA has approved 14 new medication and treatment options for the behavioral health space to date in 2022. The new medication and treatment options cover a wide range of behavioral health conditions, including schizophrenia, bipolar disorder, ADHD, and more.  What do these new care options mean for providers? In Genoa Healthcare’s recent webinar, clinical quality manager Jennifer Heath, PharmD shares more about new behavioral drugs and therapies and what they mean for those we serve. Plus, Jenn details the latest guidance on COVID-19 and other vaccinations. Check out the webinar below to learn more:

  • Explore new behavioral health drug approvals in 2022
  • Review 2021 drug approvals and the recent pace of FDA approvals
  • Examine projected drug trends in 2023

Frequently asked questions from the webinar:

What are some resources for staying up to date on new treatment options or drug approvals?

Staying up to date on pipeline medications and new drug approvals can be challenging. It takes 12 to15 years for a new drug to go from invention to market and on average only 43 novel drugs are approved each year. Here are a couple of online resources to stay in the loop on new medication options:

Free resources:

Subscribers only:

If approved, how will the new Risperidone ER (TV_46000/mdc-IRM) be administered?

TV-46000/mdc-IRM is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology, being studied for every one-month or two-month maintenance dosing for schizophrenia. It was studied for subcutaneous injection in both the abdomen and upper arm. The New Drug Application (NDA) will require resubmission by the sponsor so it is not yet known, if approved, how the medication will be recommended to be administered.

Will there be a self-administered flu vaccine in the near future?

In the past, FluMist nasal spray was studied for self-administration. A Phase IV open label study was completed in 2015 reviewing the seroresponse when FluMist was administered by a health care worker compared to self-administration. It was found that the immunogenicity was similar between either administration method.  However, to date, it has not been approved for self-administration. Shortly after the self-administration study was completed, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommended against the use of FluMist during the 2016-2017 and 2017-2018 influenza seasons due to lack of effectiveness. However, its use was resumed in 2018-2019. This was influenced by strain composition and not by administration method.

To learn more about how Genoa can help you and those you serve, contact us today.

Recent Posts

  • Blog Post
Partnering with ACT teams to make an even bigger impact

Genoa Healthcare® pharmacist Julie R. has seen firsthand the impact that severe and persistent mental illness can have on a person. For one of her consumers living with schizophrenia, the...

  • Blog Post
  • Webinar
For consumers living with Tardive Dyskinesia, Genoa Healthcare’s Clinical Assistance Program offers personalized support

Tardive Dyskinesia – a neurological disorder linked to prolonged use of antipsychotic medications – impacts over 600,000 individuals each year. Did you know that 50% of consumers taking TD medication...

  • Blog Post
A foundation to build on: 3 ways an engaged pharmacy partner helps you deliver whole-person health

A recent survey found that nearly 60% of behavioral health, primary care and complex care providers reported that their organization currently offered or had plans to begin offering integrated care...

  • Clinical Insights
  • Webinar
Understanding Tardive Dyskinesia: What you need to know

Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...